赛托生物(300583.SZ)：取得地塞米松磷酸钠原料药CEP证书

Core Viewpoint - The company Saito Bio (300583.SZ) announced that its subsidiary Shandong Sry Pharmaceutical Co., Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient Dexamethasone Sodium Phosphate [1] Group 1: Company Developments - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, has been granted a CEP certificate for Dexamethasone Sodium Phosphate, indicating compliance with European pharmacopoeia standards [1] - Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties [1] Group 2: Product Applications - The drug is primarily used for treating allergic and autoimmune inflammatory diseases, including connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, and acute leukemia [1] - It is also utilized in the comprehensive treatment of certain severe infections, poisoning, and malignant lymphomas [1]